New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
09:19 EDTAKRXAkorn to acquire VersaPharm for $440M in cash
Akorn announced that it has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440M in cash. This acquisition is expected to add $90M-$100M in annual revenues and 10c-12c in EPS, excluding new pipeline launches, deal amortization and acquisition-related expenses. Akorn intends to fund the transaction through approximately $445M in term loan borrowings. Fully committed financing for the transaction has been provided by JPMorgan Chase Bank, N.A. The acquisition will be subject to customary conditions, including termination of the waiting period under the provisions of the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. Pending the satisfaction of such customary conditions, Akorn anticipates closing the transaction in 3Q14.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
10:23 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:11 EDTAKRXAkorn initiated with Outperform, $50 target at William Blair
William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.
December 8, 2014
11:30 EDTAKRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use